First, the trial evaluated Teliso-V plus osimertinib, an EGFR TKI that is the standard of care for EGFRm NSCLC, after previous failure with osimertinib in patients with c-MET overexpressing EGFRm NSCLC [40]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.